Research programme: antisense drug therapies - Isis/Eli Lilly and Company
Latest Information Update: 29 Mar 2012
At a glance
- Originator Isis Pharmaceuticals
- Developer Eli Lilly and Company
- Class Antisense oligonucleotides
- Mechanism of Action Apoptosis stimulants; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Mar 2012 No development reported - Preclinical for Cancer in USA (Parenteral)
- 14 Apr 2009 Preclinical development is ongoing
- 20 Sep 2004 Isis Pharmaceuticals has licensed LY 2275796 to Eli Lilly and Company